Training the synergy between Bacillus Calmette-Guérin and immune checkpoint-blocking antibodies in bladder cancer

Renate Pichler; Martin Thurnher

doi:10.1002/cac2.12647

Cancer Communications ›› 2025, Vol. 45 ›› Issue (4) : 438 -441. DOI: 10.1002/cac2.12647

RESEARCH HIGHLIGHTS

Training the synergy between Bacillus Calmette-Guérin and immune checkpoint-blocking antibodies in bladder cancer

Renate Pichler ¹
, Martin Thurnher ²

Author information +

History +

PDF

Cite this article

Download citation ▾

Renate Pichler, Martin Thurnher. Training the synergy between Bacillus Calmette-Guérin and immune checkpoint-blocking antibodies in bladder cancer. Cancer Communications, 2025, 45(4): 438-441 DOI:10.1002/cac2.12647

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976; 116: 180-183.

[2]	Gontero P, Birtle A, Capoun O, Compérat E, Dominguez-Escrig JL, Liedberg F, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-A Summary of the 2024 Guidelines Update. Eur Urol. 2024; 86(6): 531-549.

[3]

Hahn NM, O'Donnell MA, Efstathiou JA, Zahurak M, Rosner GL, Smith J, et al. A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study. Eur Urol. 2023; 83(6): 486-494.

[4]	Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Ifrim DC, Saeed S, et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci U S A. 2012; 109(43): 17537-17542.

[5]	Arts RJW, Carvalho A, La Rocca C, Palma C, Rodrigues F, Silvestre R, et al. Immunometabolic Pathways in BCG-Induced Trained Immunity. Cell Rep. 2016; 17(10): 2562-2571.

[6]	Shann F. The non-specific effects of vaccines. Arch Dis Child. 2010; 95(9): 662-667.

[7]	Netea MG, Giamarellos-Bourboulis EJ, Domınguez-Andres J, Curtis N, van Crevel R, van de Veerdonk FL, et al. Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection. Cell. 2020; 181(5): 969-977.

[8]	Pichler R, Diem G, Hackl H, Koutník J, Mertens LS, D Andrea D, et al. Intravesical BCG in bladder cancer induces innate immune responses against SARS-CoV-2. Front Immunol. 2023; 14: 1202157.

[9]	van Puffelen JH, Novakovic B, van Emst L, Kooper D, Zuiverloon TCM, Oldenhof UTH, et al. Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections. J Immunother Canc. 2023; 11(1): e005518.

[10]	Atallah A, Grossman A, Nauman RW, Paré JF, Khan A, Siemens DR, et al. Systemic versus localized Bacillus Calmette Guérin immunotherapy of bladder cancer promotes an anti-tumoral microenvironment: Novel role of trained immunity. Int J Cancer. 2024; 155(2): 352-364.

[11]	Paré JF, Tabasinezhad M, Grossman A, Atallah A, Hindmarch CCT, Tyryshkin K, et al. Association of Histone H3 Trimethylation in Circulating Monocytes with Lack of Early Recurrence in Patients with Bladder Cancer following BCG Induction Therapy. Bladder Cancer. 2023; 9(2): 175-186.

[12]	Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN. The function of Fcγ receptors in dendritic cells and macrophages. Nat Rev Immunol. 2014; 14(2): 94-108.

[13]	Bond A, Fiaz S, Rollins K, Nario JEQ, Snyder ET, Atkins DJ, et al. Prior Fc receptor activation primes macrophages for increased sensitivity to IgG via long-term and short-term mechanisms. Dev Cell. 2024; S1534-5807(24)00457-X.

[14]	Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017; 545(7655): 495-499.

[15]	Leentjens J, Kox M, Stokman R, Gerretsen J, Diavatopoulos DA, van Crevel R, et al. BCG Vaccination Enhances the Immunogenicity of Subsequent Influenza Vaccination in Healthy Volunteers: A Randomized, Placebo-Controlled Pilot Study. J Infect Dis. 2015; 212(12): 1930-1938.

[16]	Um PK, Praharaj M, Lombardo KA, Yoshida T, Matoso A, Baras AS, et al. Improved bladder cancer antitumor efficacy with a recombinant BCG that releases a STING agonist. bioRxiv [Preprint]. 2023; 2023.12.15.571740.

[17]	Osorio JC, Smith P, Knorr DA, Ravetch JV. The antitumor activities of anti-CD47 antibodies require Fc-FcγR interactions. Cancer Cell. 2023; 41(12): 2051-2065. e6.